NurExone.png
NurExone Biologic to Present Exosome-Based Therapy for Spinal Cord Injury in Regenerative Medicine Session at Upcoming Extracellular Vesicles Forum
October 05, 2023 08:30 ET | NurExone Biologic Inc
NurExone Biologic will present at the EVs Forum in Cambridge presents advances in exosome therapy for spinal cord injuries, highlighting ExoPTEN potential
NurExone.png
NurExone Appoints Dr. Reuter Investor Relations in Europe
September 28, 2023 08:30 ET | NurExone Biologic Inc
NurExone partners with Dr. Reuter Investor Relations for European investor relations services. TSX approves NurExone's warrant amendments.
NurExone.png
NurExone Moves Forward Towards Human Clinical Trials, Completes Pre-IND Meeting with the FDA for Proprietary ExoPTEN Drug
September 13, 2023 08:30 ET | NurExone Biologic Inc
The FDA’s response indicated that the planned toxicity study strategy is acceptable under FDA guidelines and large-scale animal studies will not be required. The completed Pre-IND meeting with the...
NurExone.png
NurExone Announces Closing of Second Tranche of Private Placement, bringing total raise at this round to approximately CAD$1.5M
September 06, 2023 08:30 ET | NurExone Biologic Inc
TORONTO and HAIFA, Israel, Sept. 06, 2023 (GLOBE NEWSWIRE) -- NurExone Biologic Inc. (TSXV: NRX) (FSE: J90) (NRX.V) (the “Company” or “NurExone”), a biopharmaceutical company developing...
NurExone.png
NurExone Reports Second Quarter 2023 Financial Results and Provides Corporate Update
August 28, 2023 08:30 ET | NurExone Biologic Inc
Completed the first tranche of a non-brokered private placement offering of units for gross proceeds of approximately CAD$1.3 million to extend cash runway into 2024Strengthened the Board of Directors...
NurExone.png
NurExone Announces Private Placement
August 09, 2023 08:00 ET | NurExone Biologic Inc
Not for distribution to United States newswire services or for dissemination in the United States TORONTO and TEL AVIV, Israel, Aug. 09, 2023 (GLOBE NEWSWIRE) -- NurExone Biologic Inc. (TSXV:...
Fig 1.
NurExone Biologic Announces Advancements in Extracellular Vesicles Functionality with Enhanced Potency and Cellular Uptake for potentially better drug delivery
July 20, 2023 08:15 ET | NurExone Biologic Inc
TORONTO and TEL AVIV, Israel, July 20, 2023 (GLOBE NEWSWIRE) -- NurExone Biologic Inc. (TSXV: NRX) (FSE: J90) (NRX.V) (“NurExone” or the “Company”) is pleased to announce significant advancements in...
Figs. 1A-B
Regeneration and Reinnervation of Spinal Cord in Rats Treated with NurExone's Intranasal ExoPTEN
June 22, 2023 08:00 ET | NurExone Biologic Inc
TORONTO and TEL AVIV, Israel, June 22, 2023 (GLOBE NEWSWIRE) -- NurExone Biologic Inc. ("NurExone" or the "Company") (TSXV: NRX) (FSE: J90) (NRX.V), is pleased to report positive imaging results...
NurExone.png
NurExone and Particle Metrix Announce Collaboration in Extracellular Vesicles Analysis Using State-of-the-art Analytic Device
June 01, 2023 08:00 ET | NurExone Biologic Inc
MUNICH, Germany and TEL AVIV, Israel, June 01, 2023 (GLOBE NEWSWIRE) -- NurExone Biologic Inc. (the "Company" or "NurExone") (TSXV: NRX) (FSE: J90), a biopharmaceutical company developing...
NurExone.png
NurExone Reports First Quarter 2023 Financial Results and Provides Corporate Update
May 24, 2023 07:19 ET | NurExone Biologic Inc
TORONTO and TEL AVIV, Israel, May 24, 2023 (GLOBE NEWSWIRE) -- NurExone Biologic Inc. (the "Company" or "NurExone") (TSXV: NRX) (FSE: J90) (NRX.V), a biopharmaceutical company developing...